Peptide therapeutics occupy an important position between conventional small molecules and biological medicines. Their development requires specialized synthetic chemistry, purification, solid-state understanding and analytical characterization. Peptide manufacturing can involve solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid approaches or recombinant technologies, depending on the molecule and its complexity. Shilpa Pharma's current CDMO platform specifically identifies peptide synthesis strategy and route scouting as part of its end-to-end peptide CDMO services.
A peptide development program must address sequence and synthetic strategy, protection/deprotection chemistry, coupling efficiency, impurity formation, cleavage and isolation, purification, solid-state properties, analytical characterization, scale-up, process safety and regulatory documentation.
A laboratory process that produces a peptide successfully may not automatically translate to commercial manufacturing. Process development therefore needs to consider the full path: route, chemistry, purification, isolation, scale-up, quality and commercial supply. Early identification of process risks can significantly improve development efficiency. Shilpa Pharma states that its manufacturing capabilities include peptides, polymers, HPAPIs, ADC linkers and specialty chemicals, alongside small-molecule API development and manufacturing.
Peptide CDMO programs benefit from early integration of chemistry, process development, analytical science, manufacturing and regulatory strategy. A development partner capable of supporting the complete lifecycle can help reduce technology-transfer complexity as programs progress toward clinical and commercial supply.
